Kylie M. Quinn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kylie M. Quinn has a total of 849 co-authors. Here are the top co-authors by number of shared publications:
- Nicole Louise La Gruta
Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
13 shared publications Jasmine Li
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia
6 shared publicationsPatricia A Darrah
Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA
6 shared publications- David Anthony Price
Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK
5 shared publications - Katherine Kedzierska
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Australia
5 shared publications Robert A Seder
Cellular Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; and
5 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wiley in Aging Cell
- Vol. 25 (11)
Establishing a Biophotonic Signature of Brain Ageing
Ageing‐associated inflammation (“inflammaging”) is characterised by chronic microglial priming or overactivity that elevates neurodegeneration risk. Microglia also accumulate autofluorescent lipofuscin as they age–aggregates of oxidised lipids, misfolded proteins and metals that generate reactive oxygen species. Characterising age‐related changes in brain autofluorescence could provide insight into brain ageing dynamics and could identify associations with potential biomarkers in accessible tissues such as blood. We hypothesised that the ageing‐related increase in microglial autofluorescent material produces a spectral signature that makes ageing autofluorescence distinct from that in young brains. To test this, we examined autofluorescence profiles in the hippocampus and arcuate nucleus (ARC) of young (3 months) and aged (21 months) female C57BL/6 mice. We found that ageing significantly increased the volume of the autofluorescent material in microglia, including driving an abundance of extra‐large aggregates. In the ARC, larger aggregates–present only in aged brains–exhibited stronger far‐red emission than the autofluorescence seen in young brains. Fluorescence lifetime imaging analysis indicated specific ageing‐related molecular changes in brain autofluorescence. Lipidomic analysis from the plasma of these mice indicated 22 lipids that were differentially concentrated with age and one (sphingomyelin 32:2) that was significantly associated with the ageing brain spectral profile after controlling for multiple comparisons and validating in a separate cohort. These findings demonstrate that autofluorescent material aggregates with age in microglia and that brain autofluorescence undergoes a spectral red‐shift associated with ageing and lipid alterations. Brain autofluorescence may thus reflect brain ageing with potential translational relevance for non‐invasive monitoring.
- 1 November 2026
- Published by Wiley in Aging Cell
- Vol. 25 (11)
Open AccessEstablishing a Biophotonic Signature of Brain Ageing
Ageing‐associated inflammation (“inflammaging”) is characterised by chronic microglial priming or overactivity that elevates neurodegeneration risk. Microglia also accumulate autofluorescent lipofuscin as they age–aggregates of oxidised lipids, misfolded proteins and metals that generate reactive oxygen species. Characterising age‐related changes in brain autofluorescence could provide insight into brain ageing dynamics and could identify associations with potential biomarkers in accessible tissues such as blood. We hypothesised that the ageing‐related increase in microglial autofluorescent material produces a spectral signature that makes ageing autofluorescence distinct from that in young brains. To test this, we examined autofluorescence profiles in the hippocampus and arcuate nucleus (ARC) of young (3 months) and aged (21 months) female C57BL/6 mice. We found that ageing significantly increased the volume of the autofluorescent material in microglia, including driving an abundance of extra‐large aggregates. In the ARC, larger aggregates–present only in aged brains–exhibited stronger far‐red emission than the autofluorescence seen in young brains. Fluorescence lifetime imaging analysis indicated specific ageing‐related molecular changes in brain autofluorescence. Lipidomic analysis from the plasma of these mice indicated 22 lipids that were differentially concentrated with age and one (sphingomyelin 32:2) that was significantly associated with the ageing brain spectral profile after controlling for multiple comparisons and validating in a separate cohort. These findings demonstrate that autofluorescent material aggregates with age in microglia and that brain autofluorescence undergoes a spectral red‐shift associated with ageing and lipid alterations. Brain autofluorescence may thus reflect brain ageing with potential translational relevance for non‐invasive monitoring.
- Open Access
- 12 March 2026
- Published by Wiley in Immunology & Cell Biology
- Vol. 104 (4) , 400-414
Age‐related differences in mRNA vaccine immunogenicity and adjuvancy
Older people mount poorer adaptive immune responses to mRNA vaccines, leaving them more vulnerable to infection with SARS‐CoV‐2. To design better mRNA vaccines for older people, we need to understand how aging alters mechanisms of adjuvancy that shape immunogenicity. To first define age‐related changes in immunogenicity, we vaccinated young (< 5 months old) and aged (> 18 months old) C57BL/6 mice with an mRNA vaccine encoding the SARS‐CoV‐2 spike protein. T cell responses were markedly reduced in aged mice at peak and memory timepoints, using intracellular cytokine staining or activation‐induced marker assays. Spike and receptor‐binding domain binding and neutralizing antibody titers were also markedly reduced in aged mice, consistent with deficits seen in older humans. To define age‐related changes in adjuvancy mechanisms, we vaccinated young and aged mice with mRNA vaccines loaded with DiD lipid dye or mScarlet mRNA, then tracked dendritic cell (DC) numbers, phenotype, vaccine uptake, antigen expression, and activation, as well as local and systemic cytokine production. DC numbers in the draining lymph nodes (dLN) were dramatically reduced before and early after vaccination in aged compared to young mice, with delayed recruitment of DCs to the dLN. Vaccine uptake was not impacted by age, but the frequency of DCs expressing antigen increased with age and DC activation decreased with age. Aging accelerated the expression of some cytokines (IL‐1α, IL‐6), while delaying others (IFNγ, MCP‐1) in dLNs and sera. This illustrates that aging impairs multiple adjuvancy mechanisms but mRNA vaccine strategies that address these age‐related deficits could improve responses in older people.
- 12 March 2026
- Published by Wiley in Immunology & Cell Biology
- Vol. 104 (4) , 400-414
Open AccessAge‐related differences in mRNA vaccine immunogenicity and adjuvancy
Older people mount poorer adaptive immune responses to mRNA vaccines, leaving them more vulnerable to infection with SARS‐CoV‐2. To design better mRNA vaccines for older people, we need to understand how aging alters mechanisms of adjuvancy that shape immunogenicity. To first define age‐related changes in immunogenicity, we vaccinated young (< 5 months old) and aged (> 18 months old) C57BL/6 mice with an mRNA vaccine encoding the SARS‐CoV‐2 spike protein. T cell responses were markedly reduced in aged mice at peak and memory timepoints, using intracellular cytokine staining or activation‐induced marker assays. Spike and receptor‐binding domain binding and neutralizing antibody titers were also markedly reduced in aged mice, consistent with deficits seen in older humans. To define age‐related changes in adjuvancy mechanisms, we vaccinated young and aged mice with mRNA vaccines loaded with DiD lipid dye or mScarlet mRNA, then tracked dendritic cell (DC) numbers, phenotype, vaccine uptake, antigen expression, and activation, as well as local and systemic cytokine production. DC numbers in the draining lymph nodes (dLN) were dramatically reduced before and early after vaccination in aged compared to young mice, with delayed recruitment of DCs to the dLN. Vaccine uptake was not impacted by age, but the frequency of DCs expressing antigen increased with age and DC activation decreased with age. Aging accelerated the expression of some cytokines (IL‐1α, IL‐6), while delaying others (IFNγ, MCP‐1) in dLNs and sera. This illustrates that aging impairs multiple adjuvancy mechanisms but mRNA vaccine strategies that address these age‐related deficits could improve responses in older people.
- Open Access
- 22 February 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Microglial Autofluorescence in the Brain and Retina is Dynamically Modulated by Systemic Inflammation
The retina—an extension of the central nervous system—contains microglia that survey and respond to injury or pathogens. In response to their environmental milieu, these cells accumulate autofluorescent material likely reflective of cellular debris. Measuring these autofluorescence changes may be a useful tool for early diagnosis of brain-related inflammatory conditions or diseases by imaging the eye. To assess this, we gave Wistar rats a systemic immune challenge with lipopolysaccharide (LPS; 250 µg/kg, intraperitoneally) and examined autofluorescence characteristics of the microglia in brain and eye using confocal microscopy. Initial flow cytometry experiments verified that isolated microglia are highly autofluorescent compared to cells in immune-related organs such as spleen. In immunolabelled brain sections (arcuate, hippocampus, retrosplenial cortex), astrocytes, neurons, and microglia all displayed significant autofluorescence, with microglia displaying greatest levels. LPS led to predicted changes in microglial morphology in the brain and this was accompanied by an increase in the number of individual autofluorescent aggregates but a reduction in the total volume, indicative of changes in the dynamics of the material. While there were similarities in the microglial response to LPS in the retina, and the total volume of autofluorescence aggregates was also reduced, retinal autofluorescence changes did not simply predict those seen in brain. These findings suggest that the relationship between immune challenge states and autofluorescence accumulation is dynamic and complex. Understanding the role of microglia in accumulating and metabolising this autofluorescent material may assist our understanding of disease states and how they influence retina and brain. Graphical Abstract
- 22 February 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Open AccessMicroglial Autofluorescence in the Brain and Retina is Dynamically Modulated by Systemic Inflammation
The retina—an extension of the central nervous system—contains microglia that survey and respond to injury or pathogens. In response to their environmental milieu, these cells accumulate autofluorescent material likely reflective of cellular debris. Measuring these autofluorescence changes may be a useful tool for early diagnosis of brain-related inflammatory conditions or diseases by imaging the eye. To assess this, we gave Wistar rats a systemic immune challenge with lipopolysaccharide (LPS; 250 µg/kg, intraperitoneally) and examined autofluorescence characteristics of the microglia in brain and eye using confocal microscopy. Initial flow cytometry experiments verified that isolated microglia are highly autofluorescent compared to cells in immune-related organs such as spleen. In immunolabelled brain sections (arcuate, hippocampus, retrosplenial cortex), astrocytes, neurons, and microglia all displayed significant autofluorescence, with microglia displaying greatest levels. LPS led to predicted changes in microglial morphology in the brain and this was accompanied by an increase in the number of individual autofluorescent aggregates but a reduction in the total volume, indicative of changes in the dynamics of the material. While there were similarities in the microglial response to LPS in the retina, and the total volume of autofluorescence aggregates was also reduced, retinal autofluorescence changes did not simply predict those seen in brain. These findings suggest that the relationship between immune challenge states and autofluorescence accumulation is dynamic and complex. Understanding the role of microglia in accumulating and metabolising this autofluorescent material may assist our understanding of disease states and how they influence retina and brain. Graphical Abstract
- Open Access
- 22 July 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 420-431
A timeline of reckoning: Tracking the historical rise of antimicrobial resistance across HIV, TB, and malaria
- 22 July 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 420-431
Open AccessA timeline of reckoning: Tracking the historical rise of antimicrobial resistance across HIV, TB, and malaria
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 327 (4) , H967-H977
Gestational influenza A virus infection elicits nonresolving vascular dysfunction and T-cell accumulation in the aorta of mice
Pregnancy is a risk factor for cardiovascular complications to influenza A virus (IAV) infection. We demonstrate that gestational IAV infection caused endothelial dysfunction of the maternal aorta, which persisted for 60 days postinfection in mice. Various T cells accumulated within the aorta at 60 days because of the infection, and this was associated with elevated levels of the proinflammatory cytokine, IFN-γ. Our study demonstrates a novel “long influenza” cardiovascular phenotype in female mice.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 327 (4) , H967-H977
Gestational influenza A virus infection elicits nonresolving vascular dysfunction and T-cell accumulation in the aorta of mice
Pregnancy is a risk factor for cardiovascular complications to influenza A virus (IAV) infection. We demonstrate that gestational IAV infection caused endothelial dysfunction of the maternal aorta, which persisted for 60 days postinfection in mice. Various T cells accumulated within the aorta at 60 days because of the infection, and this was associated with elevated levels of the proinflammatory cytokine, IFN-γ. Our study demonstrates a novel “long influenza” cardiovascular phenotype in female mice.
- Top Cited PapersOpen Access
- 22 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Piezo1 expression in neutrophils regulates shear-induced NETosis
Neutrophil infiltration and subsequent extracellular trap formation (NETosis) is a contributing factor in sterile inflammation. Furthermore, neutrophil extracellular traps (NETs) are prothrombotic, as they provide a scaffold for platelets and red blood cells to attach to. In circulation, neutrophils are constantly exposed to hemodynamic forces such as shear stress, which in turn regulates many of their biological functions such as crawling and NETosis. However, the mechanisms that mediate mechanotransduction in neutrophils are not fully understood. In this study, we demonstrate that shear stress induces NETosis, dependent on the shear stress level, and increases the sensitivity of neutrophils to NETosis-inducing agents such as adenosine triphosphate and lipopolysaccharides. Furthermore, shear stress increases intracellular calcium levels in neutrophils and this process is mediated by the mechanosensitive ion channel Piezo1. Activation of Piezo1 in response to shear stress mediates calpain activity and cytoskeleton remodeling, which consequently induces NETosis. Thus, activation of Piezo1 in response to shear stress leads to a stepwise sequence of cellular events that mediates NETosis and thereby places neutrophils at the centre of localized inflammation and prothrombotic effects.
- 22 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Top Cited PapersOpen AccessPiezo1 expression in neutrophils regulates shear-induced NETosis
Neutrophil infiltration and subsequent extracellular trap formation (NETosis) is a contributing factor in sterile inflammation. Furthermore, neutrophil extracellular traps (NETs) are prothrombotic, as they provide a scaffold for platelets and red blood cells to attach to. In circulation, neutrophils are constantly exposed to hemodynamic forces such as shear stress, which in turn regulates many of their biological functions such as crawling and NETosis. However, the mechanisms that mediate mechanotransduction in neutrophils are not fully understood. In this study, we demonstrate that shear stress induces NETosis, dependent on the shear stress level, and increases the sensitivity of neutrophils to NETosis-inducing agents such as adenosine triphosphate and lipopolysaccharides. Furthermore, shear stress increases intracellular calcium levels in neutrophils and this process is mediated by the mechanosensitive ion channel Piezo1. Activation of Piezo1 in response to shear stress mediates calpain activity and cytoskeleton remodeling, which consequently induces NETosis. Thus, activation of Piezo1 in response to shear stress leads to a stepwise sequence of cellular events that mediates NETosis and thereby places neutrophils at the centre of localized inflammation and prothrombotic effects.
- 24 April 2024
- Published by Wiley in Immunology & Cell Biology
- Vol. 102 (6) , 432-436
Highlight of 2023: Virtues and vices of CD4 CAR T cells
This article for the Highlights of 2023 Series explores recent work that suggests that targeting CD4 CAR T cells may be critical for both of these challenges.
- 24 April 2024
- Published by Wiley in Immunology & Cell Biology
- Vol. 102 (6) , 432-436
Highlight of 2023: Virtues and vices of CD4 CAR T cells
This article for the Highlights of 2023 Series explores recent work that suggests that targeting CD4 CAR T cells may be critical for both of these challenges.
- Top Cited PapersOpen Access
- 10 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8010) , 201-210
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma1–4, but the efficacy of CAR T cell therapy in solid tumours has been limited5. This is owing to a number of factors, including the immunosuppressive tumour microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. Analysis of anti-CD19 CAR T cells used clinically has shown that positive treatment outcomes are associated with a more ‘stem-like’ phenotype and increased mitochondrial mass6–8. We therefore sought to identify transcription factors that could enhance CAR T cell fitness and efficacy against solid tumours. Here we show that overexpression of FOXO1 promotes a stem-like phenotype in CAR T cells derived from either healthy human donors or patients, which correlates with improved mitochondrial fitness, persistence and therapeutic efficacy in vivo. This work thus reveals an engineering approach to genetically enforce a favourable metabolic phenotype that has high translational potential to improve the efficacy of CAR T cells against solid tumours.
- 10 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8010) , 201-210
Top Cited PapersOpen AccessFOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma1–4, but the efficacy of CAR T cell therapy in solid tumours has been limited5. This is owing to a number of factors, including the immunosuppressive tumour microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. Analysis of anti-CD19 CAR T cells used clinically has shown that positive treatment outcomes are associated with a more ‘stem-like’ phenotype and increased mitochondrial mass6–8. We therefore sought to identify transcription factors that could enhance CAR T cell fitness and efficacy against solid tumours. Here we show that overexpression of FOXO1 promotes a stem-like phenotype in CAR T cells derived from either healthy human donors or patients, which correlates with improved mitochondrial fitness, persistence and therapeutic efficacy in vivo. This work thus reveals an engineering approach to genetically enforce a favourable metabolic phenotype that has high translational potential to improve the efficacy of CAR T cells against solid tumours.
- Open Access
- 1 January 2024
- Published by Wiley in Clinical & Translational Immunology
- Vol. 13 (12) , e70016
Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals
Objectives: In clinical chimeric antigen receptor (CAR) T cell therapy, one of the strongest correlates of favorable patient responses is lower levels of differentiation in T cells from the peripheral blood mononuclear cell (PBMC) starting material or the CAR T cell product. T cells from older patients are inherently more differentiated, but we hypothesised that specific activation protocols could be used to limit CAR T cell differentiation during manufacturing, particularly in older patients.Methods: We used PBMCs from young (20–30 years old) and older (60+ years old) healthy donors to generate CAR T cells using two activation protocols: soluble anti‐(α) CD3 monoclonal antibody (mAb) vs immune complexes of αCD3 and αCD28 mAbs. Products were assessed for yield, function and differentiation, which was used as a measure of CAR T cell quality. T cells in PBMCs were assessed for CD28 expression and correlative analyses were performed.Results: Older samples generated fewer, more differentiated CAR T cells than young samples, and the αCD3/CD28 mAb protocol exacerbated this, further reducing yield and quality. CD28 expression by T cells correlated with CAR T cell differentiation, but T cell differentiation in PBMC starting material was a stronger correlate of CAR T cell differentiation.Conclusions: Choice of activation protocol can substantially impact on the yield and quality of CAR T cells during manufacturing. This is a key consideration for older patients whose samples already generate a poorer yield and lower quality of CAR T cells.
- 1 January 2024
- Published by Wiley in Clinical & Translational Immunology
- Vol. 13 (12) , e70016
Open AccessChoice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals
Objectives: In clinical chimeric antigen receptor (CAR) T cell therapy, one of the strongest correlates of favorable patient responses is lower levels of differentiation in T cells from the peripheral blood mononuclear cell (PBMC) starting material or the CAR T cell product. T cells from older patients are inherently more differentiated, but we hypothesised that specific activation protocols could be used to limit CAR T cell differentiation during manufacturing, particularly in older patients.Methods: We used PBMCs from young (20–30 years old) and older (60+ years old) healthy donors to generate CAR T cells using two activation protocols: soluble anti‐(α) CD3 monoclonal antibody (mAb) vs immune complexes of αCD3 and αCD28 mAbs. Products were assessed for yield, function and differentiation, which was used as a measure of CAR T cell quality. T cells in PBMCs were assessed for CD28 expression and correlative analyses were performed.Results: Older samples generated fewer, more differentiated CAR T cells than young samples, and the αCD3/CD28 mAb protocol exacerbated this, further reducing yield and quality. CD28 expression by T cells correlated with CAR T cell differentiation, but T cell differentiation in PBMC starting material was a stronger correlate of CAR T cell differentiation.Conclusions: Choice of activation protocol can substantially impact on the yield and quality of CAR T cells during manufacturing. This is a key consideration for older patients whose samples already generate a poorer yield and lower quality of CAR T cells.
- Open Access
- 3 November 2023
- Published by Springer Nature in Research Square
Overexpression of FOXO1 enhances CAR T cell polyfunctionality, metabolic fitness and efficacy against solid tumors
The efficacy of chimeric antigen receptor (CAR) T cell therapy is limited in solid tumors by several factors including the immunosuppressive tumor microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. To overcome this, we sought to identify transcription factors that could enhance CAR T cell fitness. We identified that the overexpression of Foxo1 could enhance the therapeutic efficacy of murine CAR T cells in the setting of syngeneic immunocompetent models and was dependent on the sustained production of proinflammatory cytokines. FOXO1 overexpression in human CAR T cells enforced broad transcriptional and epigenetic changes that led to a more “stem-like” phenotype and similarly improved therapeutic efficacy. Enhanced efficacy was associated with improved mitochondrial fitness and persistence in vivo. FOXO1 overexpression also led to a more stem like phenotype in patient derived CAR T cells and is therefore a promising strategy for the treatment of solid cancers.
- 3 November 2023
- Published by Springer Nature in Research Square
Open AccessOverexpression of FOXO1 enhances CAR T cell polyfunctionality, metabolic fitness and efficacy against solid tumors
The efficacy of chimeric antigen receptor (CAR) T cell therapy is limited in solid tumors by several factors including the immunosuppressive tumor microenvironment that gives rise to poorly persisting and metabolically dysfunctional T cells. To overcome this, we sought to identify transcription factors that could enhance CAR T cell fitness. We identified that the overexpression of Foxo1 could enhance the therapeutic efficacy of murine CAR T cells in the setting of syngeneic immunocompetent models and was dependent on the sustained production of proinflammatory cytokines. FOXO1 overexpression in human CAR T cells enforced broad transcriptional and epigenetic changes that led to a more “stem-like” phenotype and similarly improved therapeutic efficacy. Enhanced efficacy was associated with improved mitochondrial fitness and persistence in vivo. FOXO1 overexpression also led to a more stem like phenotype in patient derived CAR T cells and is therefore a promising strategy for the treatment of solid cancers.